Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

Study Overview
=================
Brief Summary
-----------------
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.

Detailed Description
-----------------
This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.

Official Title
-----------------
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder Male and female patients aged 19 59 Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics Clinically stable and able to complete the questionnaires Patients who sufficiently understand the objective of the study and sign informed consent form Exclusion Criteria: Patients having any medical illness or taking any medicine affecting appetite and body weight Patients with severe and unstable medical, neurological or systemic illnesses Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders. Pregnant or breast-feeding women

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Risperidone<br>Receiving risperidone treatment | |
| Olanzapine<br>Receiving olanzapine treatment | |
| Aripiprazole<br>Receiving aripiprazole | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in appetite and eating behavior Rating Scales: Drug-related eating behavior questionnaire & Korean version of General Food Craving Questionnaire |  | between 2 and 24months after starting medication | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index (BMI) |  | between 2 and 24 months after starting medication | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, atypical antipsychotics, appetite, eating behavior